Wirtz H, Schmidt M
Medizinische Klinik, Universität Würzburg.
Clin Investig. 1992 Jan;70(1):3-13. doi: 10.1007/BF00422930.
Various factors are involved in the regulation of surfactant secretion: chemical agonist; local environmental factors such as mediators, locally produced hormones, and possibly pH; and finally, mechanical stress occurring during lung inflation. Here we suggest a model of regulation which is grouped into three levels: a basal autoregulatory mechanism with local factors being superimposed and a systemic level acting through hormones reaching the lung via the bloodstream. Depending on the situation, the different levels may vary in their importance. For the normal situation, in the absence of stress factors, we suggest the autoregulation of stretch-induced secretion and SP-A inhibition as indicated by in vitro experiments to be the prominent regulatory mechanism for surfactant secretion. From this model, mechanisms can be derived which indicate involvement of the surfactant system in, for example, obstructive lung disease. Support from the literature for this hypothesis is reviewed. Because quantitative measurement of the amount of surfactant-associated phospholipids cannot be done adequately at this time, we suggest testing the relatively risk-free application of exogenous surfactant in a pilot phase based on indications for its involvement and usefulness derived from animal and in vitro experiments.
化学激动剂;局部环境因素,如介质、局部产生的激素以及可能的pH值;最后,肺膨胀过程中产生的机械应力。在此,我们提出一种调节模型,该模型分为三个层次:一种基础的自动调节机制,局部因素叠加其上,以及一个通过血液中到达肺部的激素起作用的全身层次。根据具体情况,不同层次的重要性可能会有所不同。对于正常情况,在没有应激因素时,我们认为如体外实验所示的拉伸诱导分泌的自动调节和SP - A抑制是表面活性剂分泌的主要调节机制。从这个模型中,可以推导出表明表面活性剂系统参与例如阻塞性肺病的机制。本文回顾了该假设在文献中的支持情况。由于目前尚无法充分定量测量表面活性剂相关磷脂的量,我们建议基于动物和体外实验得出的其参与情况和有用性的指征,在试点阶段测试外源性表面活性剂相对无风险的应用。